Ampio Pharmaceuticals Inc (AMPE):企業の財務・戦略的SWOT分析

◆英語タイトル:Ampio Pharmaceuticals Inc (AMPE) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH230074FSA
◆発行会社(調査会社):GlobalData
◆発行日:2021年4月
◆ページ数:25
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD600 ⇒換算¥88,800見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD900 ⇒換算¥133,200見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Ampio Pharmaceuticals Inc (Ampio) formerly Chay Enterprises Inc, operates as a bio pharmaceutical company that discovers and develops novel therapeutic candidates for inflammatory conditions. The company develops compounds that decrease inflammation by inhibiting specific pro-inflammatory compounds by affecting specific pathways at the protein expression and at the transcription level. It provides products for the treatment of osteoarthritis, diabetic macular edema, and other prevalent, inflammatory diseases. Ampio’s products include low molecular weight fraction of human serum albumin and ultra-low dose of danazol. Its ultra-low dose of danazol is used for the oral treatment of diabetic macular edema. The company conducts research on various future indications for optina. It partners with other bio pharmaceutical companies for its research activities. Ampio is headquartered in Englewood, Colorado, the US.

Ampio Pharmaceuticals Inc Key Recent Developments

Apr 07,2021: Valneva’s Covid-19 vaccine shows robust immune response in trial
Mar 19,2021: Ampio Pharmaceuticals to Present at Benzinga Biotech Small Cap Conference
Mar 10,2021: Ampio Pharmaceuticals to Participate in the 33rd Annual Virtual ROTH Conference on March 15-17, 2021
Mar 03,2021: Ampio pharmaceuticals reports fourth quarter 2020 financial results and provides business update
Feb 16,2021: Ampio Pharmaceuticals, Inc. to Present at Upcoming Investor Conference

This comprehensive SWOT profile of Ampio Pharmaceuticals Inc provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

This company report forms part of GlobalData’s ‘Profile on Demand’ service, covering over 50,000 of the world’s leading companies. Once purchased, GlobalData’s highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of Ampio Pharmaceuticals Inc including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days. (excluding weekends).

The profile contains critical company information including*,

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note*: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include,

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

【レポートの目次】

Table of Contents

Section 1 – About the Company

Ampio Pharmaceuticals Inc – Key Information
Ampio Pharmaceuticals Inc – Overview
Ampio Pharmaceuticals Inc – Key Employees
Ampio Pharmaceuticals Inc – Key Employee Biographies
Ampio Pharmaceuticals Inc – Key Operational Heads
Ampio Pharmaceuticals Inc – Major Products and Services
Ampio Pharmaceuticals Inc – History
Ampio Pharmaceuticals Inc – Company Statement
Ampio Pharmaceuticals Inc – Locations And Subsidiaries
Ampio Pharmaceuticals Inc
Head Office
Other Locations & Subsidiaries

Section 2 – Company Analysis

Ampio Pharmaceuticals Inc – Business Description
Ampio Pharmaceuticals Inc – Corporate Strategy
Ampio Pharmaceuticals Inc – SWOT Analysis
SWOT Analysis – Overview
Ampio Pharmaceuticals Inc – Strengths
Ampio Pharmaceuticals Inc – Weaknesses
Ampio Pharmaceuticals Inc – Opportunities
Ampio Pharmaceuticals Inc – Threats
Ampio Pharmaceuticals Inc – Key Competitors

Section 3 – Company Financial Performance Charts

Ampio Pharmaceuticals Inc – Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts

Section 4 – Appendix

Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

Note*: Some sections may be missing if data is unavailable for the company

List of Tables

Ampio Pharmaceuticals Inc, Key Information
Ampio Pharmaceuticals Inc, Key Ratios
Ampio Pharmaceuticals Inc, Share Data
Ampio Pharmaceuticals Inc, Major Products and Services
Ampio Pharmaceuticals Inc, History
Ampio Pharmaceuticals Inc, Key Employees
Ampio Pharmaceuticals Inc, Key Employee Biographies
Ampio Pharmaceuticals Inc, Key Operational Heads
Ampio Pharmaceuticals Inc, Other Locations
Ampio Pharmaceuticals Inc, Subsidiaries
Ampio Pharmaceuticals Inc, Key Competitors
Ampio Pharmaceuticals Inc, SWOT Analysis
Ampio Pharmaceuticals Inc, Ratios based on current share price
Ampio Pharmaceuticals Inc, Annual Ratios
Ampio Pharmaceuticals Inc, Interim Ratios
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[Ampio Pharmaceuticals Inc (AMPE):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • DCP Midstream LP (DCP):企業の財務・戦略的SWOT分析
    DCP Midstream LP (DCP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Greatcell Solar Ltd (GSL)-エネルギー分野:企業M&A・提携分析
    Summary Greatcell Solar Ltd (Greatcell Solar), formerly Dyesol Limited, is a renewable energy company that develops and commercializes Perovskite Solar Cells (PSC) or solid-state dye solar cell (DSC), the third generation photovoltaic technology. The company develops a range of PSC chemicals, compon …
  • Royal Orchid Hotels Ltd:企業の戦略・SWOT・財務分析
    Royal Orchid Hotels Ltd - Strategy, SWOT and Corporate Finance Report Summary Royal Orchid Hotels Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Central Electricity Generating Co:企業の発電所・SWOT分析2018
    Central Electricity Generating Co - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on …
  • Batu Biologics Inc-製薬・医療分野:企業M&A・提携分析
    Summary Batu Biologics Inc (Batu Biologics) is a biotechnology based pharmaceutical company which develops and commercializes novel cell and gene therapies. Its lead product, ValloVax, a cellular anti-angiogenic cancer vaccine, is developed to induce an immune response against the tumor endothelium …
  • Cryosite Ltd (CTE):企業の財務・戦略的SWOT分析
    Summary Cryosite Ltd (Cryosite) is a healthcare solution provider that offers clinical trials outsourced logistics services to research, medical, pharmaceutical, veterinary and biotechnology industries. The company manufactures stem cell products for both therapeutic use and clinical trials. It prov …
  • Ardelyx Inc (ARDX):企業の財務・戦略的SWOT分析
    Summary Ardelyx Inc (Ardelyx) is a developer of small molecule therapeutics for treatment of cardio-renal, gastrointestinal and metabolic disorders. The company provides product portfolio such as tenapanor, RDX227675, RDX98940 and RDX013, among others. Its products are used for hyperphosphatemia in …
  • Shenergy Co., Ltd. (600642):電力:M&Aディール及び事業提携情報
    Summary Shenergy Company, Ltd. (Shenergy) is China-based gas and electricity company. The company is engaged in the construction, investment, operations and management of petroleum, natural gas and electric power. Its electricity projects include hydropower, coal-fired power and thermal power genera …
  • Sumitomo Seika Chemicals Co Ltd (4008):企業の財務・戦略的SWOT分析
    Sumitomo Seika Chemicals Co Ltd (4008) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths a …
  • Nuclear Power Corporation of India Ltd:企業の戦略的SWOT分析
    Nuclear Power Corporation of India Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and ma …
  • Coffee Republic Trading Ltd:企業の戦略・SWOT・財務分析
    Coffee Republic Trading Ltd - Strategy, SWOT and Corporate Finance Report Summary Coffee Republic Trading Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Olon SpA:製薬・医療:M&Aディール及び事業提携情報
    Summary Olon SpA (Olon), formerly Antibioticos SpA, a susbsidiary of P&R S.p.A. is a developer and producer of active pharmaceutical ingredients. The company offers products such as azacitidine, bezafibrate, ibuprofen sodium, acamprosate calcium, acebutolol hydrochloride, acitretin, thalidomide, aba …
  • EOH Holdings Ltd (EOH):企業の財務・戦略的SWOT分析
    EOH Holdings Ltd (EOH) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Orange SA (ORA):企業の財務・戦略的SWOT分析
    Orange SA (ORA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • IntegraGen SA (ALINT):医療機器:M&Aディール及び事業提携情報
    Summary IntegraGen SA (IntegraGen) is a developer and commercializer of molecular diagnostic tests for the treatment of autism and oncology. The company provides advanced genomic and bioinformatic services, including clinical research, basic and human genetic research, bioinformatics and bioanalysis …
  • National Comprehensive Cancer Network:製薬・医療:M&Aディール及び事業提携情報
    Summary National Comprehensive Cancer Network (NCCN) is a not-for-profit cancer center that offers patient care, research, and education services. The center offers research and medical information to help patients and health professionals related to cancer care. It provides subscriptions and produc …
  • Kyorin Pharmaceutical Co Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Kyorin Pharmaceutical Co Ltd (Kyorin), a subsidiary of Kyorin Holdings Inc, is a pharmaceutical company that manufactures and markets prescription medicines. The company offers ethical drugs including mucodyne, kipres, desalex, flutiform, pentasa, ketas and uritos. Its ketas product is a pho …
  • Yingli Green Energy Holding Company Limited (YGE):企業の財務・戦略的SWOT分析
    Yingli Green Energy Holding Company Limited (YGE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key …
  • Sichuan Chuantou Energy Company Ltd (600674):電力:M&Aディール及び事業提携情報
    Summary Sichuan Chuantou Energy Company Ltd (Sichuan Investment Energy), a subsidiary of Sichuan Investment Group Co Ltd is an investment holding company. The company’s business activities include operation of hydropower stations, thermal power plant and power generation plants. It develops, constru …
  • The Save Mart Companies:企業の戦略・SWOT・財務情報
    The Save Mart Companies - Strategy, SWOT and Corporate Finance Report Summary The Save Mart Companies - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆